Please login to the form below

Not currently logged in
Email:
Password:

Horizon Pharma

This page shows the latest Horizon Pharma news and features for those working in and with pharma, biotech and healthcare.

Horizon sunny as thyroid eye disease drug hits the mark

Horizon sunny as thyroid eye disease drug hits the mark

New treatment helps lessen eye bulging. Horizon Pharma shares rose strongly after it reported a positive phase 3 trial of teprotumumab for the treatment of active thyroid eye disease (TED), which ... All secondary endpoints were also met, with a

Latest news

  • Horizon taps academic partner to boost gene editing platform Horizon taps academic partner to boost gene editing platform

    By extending our scientific and IP capabilities, Horizon will now be able to more fully support our pharma, biotech and academic partners to deliver better cell therapy solutions to patients.”. ... Horizon has also agreed to fund further research in

  • Horizon Discovery and C4X to harness CRISPR for new cancer drugs Horizon Discovery and C4X to harness CRISPR for new cancer drugs

    Cambridge-based Horizon has its own proprietary gene editing and gene modulation technologies. ... Horizon and C4X say pharma companies are now using traditional empirical research to identify other compounds which can produce this effect – but claim

  • CHMP backs Sanofi’s all-oral sleeping sickness drug CHMP backs Sanofi’s all-oral sleeping sickness drug

    Vertex Pharma got the okay to extend the use of its Orkambi (lumacaftor/ivacaftor) cystic fibrosis drug to include patients aged 2 to 5 years old who have two copies of ... the F508del mutation, while Horizon Pharma’s Ravicti (glycerol phenylbutyrate)

  • UK pharma cheers EU science announcement UK pharma cheers EU science announcement

    UK won't be excluded from Horizon research collaboration. Amid all the chaos and confusion of Brexit, the UK pharma industry finally has some good news to latch onto – it ... Meanwhile along with welcoming the Horizon Europe development, Porkess also re

  • What’s on the horizon? What’s on the horizon?

    The evolving role of the healthcare expert.

More from news
Approximately 4 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Abbott, Allergan, Celgene, Moderna, Pfizer and Takeda feature in this month's pharma deals round-up. ... Upfront $80m plus $830m in milestones [ex S. Korea]. 910. Raptor / Horizon Pharma.

  • Deal Watch October 2015 Deal Watch October 2015

    This was exemplified by the major asset swapping amongst pharma companies of last year. ... More big pharma acquisitions on the horizon? We cannot close this month's Deal Watch without mentioning the reports filtering out near the end of October that

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    For an indepth analysis of these deals, read'Pharma deals during March 2014'. ... Vidara Therapeutics/. Horizon Pharma. Merger/ acquisition. Actimmune (interferon gamma-1b) for CGD and SMO (approved).

  • Pharma deals during March 2014 Pharma deals during March 2014

    US-based Horizon Pharma's acquisition of Irish-based Vidara Therapeutics via a reverse merger for cash and stock comes in at $660m. ... The NewCo will be called Horizon Pharma plc and will be an Irish company to take advantage of the lower corporate tax

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Ziarco appoints Mike Grey to board of directors Ziarco appoints Mike Grey to board of directors

    Grey has served as CEO at numerous biopharma companies, including Auspex Pharma, SGZ Pharma and Trega Biosciences. ... Grey is currently on the boards of BioMarin Pharma, Horizon Pharma, Mirati Therapeutics and Selventa.

  • Horizon Discovery appoints executive director Horizon Discovery appoints executive director

    Smoller joined Horizon as chief business officer as part of the form's acquisition of Sage Labs for $48m in September this year. ... 1996. Horizon is a UK-based biotech focused on genomics research and the development of personalised medicines.

  • Horizon adds AZ’s Galbraith to board Horizon adds AZ’s Galbraith to board

    Galbraith is senior VP and head of oncology innovative medicines at AZ and knows Horizon well thanks to a collaboration between the two companies on personalised cancer treatments. ... We believe each will be an invaluable asset to Horizon, and look

  • Horizon appoints board chair Horizon appoints board chair

    Dr Gilham's prior experience also includes senior positions at leading pharma companies, such as GlaxoSmithKline and Abbott Labs. ... from his guidance as Horizon continues to develop as a world-leading translational genomics organisation.".

  • Oscar Ferenczi joins Grünenthal from Sandoz Oscar Ferenczi joins Grünenthal from Sandoz

    Will lead German pharma company's Latin American expansion plans. Grünenthal has appointed former region head of Sandoz Latin America Oscar Ferenczi to lead its own Latin America business. ... and an agreement with US-based Horizon Pharma for the

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics